AU2015200390A1 - Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same - Google Patents

Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Info

Publication number
AU2015200390A1
AU2015200390A1 AU2015200390A AU2015200390A AU2015200390A1 AU 2015200390 A1 AU2015200390 A1 AU 2015200390A1 AU 2015200390 A AU2015200390 A AU 2015200390A AU 2015200390 A AU2015200390 A AU 2015200390A AU 2015200390 A1 AU2015200390 A1 AU 2015200390A1
Authority
AU
Australia
Prior art keywords
methods
arylamino
mek
inhibitors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2015200390A
Other versions
AU2015200390B2 (en
Inventor
Stuart Dimock
Jean-Luc Girardet
Jeffrey N. Miner
Barry Quart
Colin Edward Rowlings
Jean-Michel Vernier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Priority claimed from AU2008282338A external-priority patent/AU2008282338B2/en
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Priority to AU2015200390A priority Critical patent/AU2015200390B2/en
Publication of AU2015200390A1 publication Critical patent/AU2015200390A1/en
Application granted granted Critical
Publication of AU2015200390B2 publication Critical patent/AU2015200390B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2015200390A 2007-07-30 2015-01-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same Ceased AU2015200390B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015200390A AU2015200390B2 (en) 2007-07-30 2015-01-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US11/830,733 2007-07-30
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446608P 2008-03-06 2008-03-06
US3446408P 2008-03-06 2008-03-06
US61/034,466 2008-03-06
US61/034,464 2008-03-06
US4488608P 2008-04-14 2008-04-14
US61/044,886 2008-04-14
AU2008282338A AU2008282338B2 (en) 2007-07-30 2008-07-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
AU2015200390A AU2015200390B2 (en) 2007-07-30 2015-01-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2008282338A Division AU2008282338B2 (en) 2007-07-30 2008-07-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Publications (2)

Publication Number Publication Date
AU2015200390A1 true AU2015200390A1 (en) 2015-02-19
AU2015200390B2 AU2015200390B2 (en) 2017-02-23

Family

ID=40304796

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2008282338A Ceased AU2008282338B2 (en) 2007-07-30 2008-07-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
AU2015200390A Ceased AU2015200390B2 (en) 2007-07-30 2015-01-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2008282338A Ceased AU2008282338B2 (en) 2007-07-30 2008-07-28 Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Country Status (23)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20150091434A (en)
CN (2) CN103479604B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA032294B1 (en)
EC (1) ECSP109910A (en)
HK (1) HK1147396A1 (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2011518786A (en) * 2008-04-14 2011-06-30 アルデア バイオサイエンシズ，インコーポレイティド Compositions and methods for preparation and use
MX2011002319A (en) * 2008-09-09 2011-04-05 Hoffmann La Roche Polymorphs of acyl sulfonamides.
BRPI0919473A2 (en) 2008-09-26 2017-08-29 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND THEIR USES
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
PE20120105A1 (en) 2009-03-11 2012-02-22 Ardea Biosciences Inc PHARMACEUTICAL COMBINATIONS INCLUDING REFAMETINIB
EP2488507B1 (en) 2009-10-13 2014-12-17 Allostem Therapeutics LLC Novel mek inhibitors, useful in the treatment of diseases
US8962606B2 (en) * 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
CA2833390A1 (en) * 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
UA113850C2 (en) * 2011-05-27 2017-03-27 CHIRAL SYNTHESIS N- {3,4-DIFLUTOR-2 - $ (2-FLUORO-4-IODPHENYL) AMINO] -6-METHOXYPHENYL} -1- $ 2,3-DYHYDROXYPROPYL] CYCLOPROPANSPANE
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
AU2013269809B2 (en) * 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
SG11201408067YA (en) 2012-06-04 2015-01-29 Pharmacyclics Inc Crystalline forms of a bruton's tyrosine kinase inhibitor
EP3702351B1 (en) * 2012-10-19 2023-11-22 Array Biopharma, Inc. Formulation comprising a mek inhibitor
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2016033094A1 (en) * 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
FI3265084T3 (en) 2015-03-03 2024-02-21 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
EA201992744A1 (en) * 2017-06-16 2020-05-27 Бета Фарма, Инк. PHARMACEUTICAL COMPOSITIONS N- (2- (2- (DIMETHYLAMINO) ETOXY) -4-METOXY-5 - ((4- (1-METHYL-1H-INDOL-3-IL) PYRIMIDIN-2-IL) AMINO) Phenyl) Acrylamide AND HIS SALTS
BR112021018168B1 (en) 2019-03-21 2023-11-28 Onxeo PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
KR100336699B1 (en) * 1992-08-25 2002-05-13 윌리암스 로저 에이 Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
ES2249060T3 (en) * 1999-01-13 2006-03-16 Warner-Lambert Company Llc DIARILAMINS REPLACED WITH 1-HETEROCICLE.
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
IL161036A0 (en) * 2001-09-24 2004-08-31 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
MXPA05000555A (en) * 2002-07-17 2005-04-28 Titan Pharmaceuticals Inc Combination of chemotherapeutic drugs for increasing antitumor activity.
WO2004012744A1 (en) * 2002-07-30 2004-02-12 Zentaris Gmbh Use of alkyl phosphocholines in combination with antitumor medicaments
BRPI0607537A2 (en) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd nanoparticulate quinazoline derivative formulations
CN101198582A (en) * 2005-04-22 2008-06-11 橘生药品工业株式会社 Polymorphic crystal of 4'-{2-[ (1s, 2r) - 2- hydroxy -2- (4-hydroxyphenyl) -1- methylethylamino] ethoxy} - 3 - isopropyl-3', 5' -dimethylbiphenyl - 4 - carboxylic acid hydrochloride
PT1912636E (en) * 2005-07-21 2014-07-24 Ardea Biosciences Inc N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd New crystal of piperacillin sodium-1 hydrate and method for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Similar Documents

Publication Publication Date Title
AU2015200390A1 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
HK1147396A1 (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
IL222698A0 (en) Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
WO2009042114A3 (en) Phenazine derivatives and uses thereof
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008101682A3 (en) Iminipyridine derivatives and their uses as microbiocides
MX2010003155A (en) Cyclopropyl aryl amide derivatives and uses thereof.
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
PT2125788E (en) Heterocyclic compounds, compositions comprising them and methods of their use
WO2009007535A3 (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
HRP20130585T1 (en) Alkylthiazol carbamate derivatives, preparation thereof and their use as faah inhibitors
WO2012037508A3 (en) Antibacterial agents: high-potency myxopyronin derivatives
AU2010243044A8 (en) Carbinol compound having heterocyclic linker
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
IL179076A0 (en) Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
WO2009000533A8 (en) Novel herbicides
WO2006078984A3 (en) Uses of methylphenidate derivatives
WO2006078887A3 (en) Methylphenidate derivatives and uses of them